Co-Diagnostics Inc
NASDAQ:CODX
Intrinsic Value
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. [ Read More ]
The intrinsic value of one CODX stock under the Base Case scenario is 0.58 USD. Compared to the current market price of 1.14 USD, Co-Diagnostics Inc is Overvalued by 49%.
Valuation Backtest
Co-Diagnostics Inc
Run backtest to discover the historical profit from buying and selling CODX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Co-Diagnostics Inc
Current Assets | 62.1m |
Cash & Short-Term Investments | 58.5m |
Receivables | 330.9k |
Other Current Assets | 3.3m |
Non-Current Assets | 33.2m |
Long-Term Investments | 773.4k |
PP&E | 6m |
Intangibles | 26.4m |
Current Liabilities | 5.7m |
Accounts Payable | 1.5m |
Accrued Liabilities | 3m |
Other Current Liabilities | 1.3m |
Non-Current Liabilities | 3.6m |
Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
Co-Diagnostics Inc
Revenue
|
6.8m
USD
|
Cost of Revenue
|
-4.2m
USD
|
Gross Profit
|
2.6m
USD
|
Operating Expenses
|
-45.3m
USD
|
Operating Income
|
-42.7m
USD
|
Other Expenses
|
7.4m
USD
|
Net Income
|
-35.3m
USD
|
Free Cash Flow Analysis
Co-Diagnostics Inc
CODX Profitability Score
Profitability Due Diligence
Co-Diagnostics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Co-Diagnostics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
CODX Solvency Score
Solvency Due Diligence
Co-Diagnostics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Co-Diagnostics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CODX Price Targets Summary
Co-Diagnostics Inc
According to Wall Street analysts, the average 1-year price target for CODX is 2.55 USD with a low forecast of 2.53 USD and a high forecast of 2.63 USD.
Ownership
CODX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CODX Price
Co-Diagnostics Inc
Average Annual Return | 226.35% |
Standard Deviation of Annual Returns | 513.73% |
Max Drawdown | -97% |
Market Capitalization | 35.6m USD |
Shares Outstanding | 31 260 000 |
Percentage of Shares Shorted | 1.63% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Contact
IPO
Employees
Officers
The intrinsic value of one CODX stock under the Base Case scenario is 0.58 USD.
Compared to the current market price of 1.14 USD, Co-Diagnostics Inc is Overvalued by 49%.